November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

FDA Approves Gefurulimab for Generalized Myasthenia Gravis

❤️ Conditions & Care 2 min read 👁 4

Federal regulators have approved a new injectable nanobody, gefurulimab, for adults with anti-AChR antibody-positive generalized myasthenia gravis following positive phase III trial results.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • FDA approved gefurulimab for generalized myasthenia gravis in adults with specific antibodies.
  • The phase III PREVAIL trial showed significant improvements in daily living activity scores versus placebo.
  • The drug carries a boxed warning for serious meningococcal infections and requires a REMS program.

The U.S. Food and Drug Administration has granted approval to gefurulimab, marketed as Klygefa, as a treatment for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies. The therapy functions as a dual-binding nanobody designed to block the activation of complement component 5.

Clinical Trial Findings

The regulatory decision follows the phase III PREVAIL study, which evaluated 260 participants randomized to receive either weekly subcutaneous injections of the drug or a placebo over a 26-week period. According to the data, the trial achieved its primary endpoint by demonstrating a statistically significant improvement in scores on the Myasthenia Gravis Activities of Daily Living scale compared with the placebo group at week 28. Researchers noted that functional improvements began as early as the first week of treatment and persisted throughout the study.

Key secondary endpoints, including Quantitative Myasthenia Gravis scores, also reflected favorable changes by week four. The therapy's design allows for once-weekly dosing by binding to serum albumin to extend its half-life. Open-label extension data further indicated that these functional benefits were maintained through 52 weeks.

Safety and Precautions

Regarding safety, the incidence of treatment-emergent adverse events was comparable between the therapy and placebo arms, with most incidents categorized as mild to moderate. The most frequently reported adverse events among patients receiving the drug included injection site reactions, headaches, and back pain. Serious adverse events occurred in 12 individuals, alongside a single death deemed unrelated to the treatment.

Because of safety considerations, the medication is subject to a risk evaluation and mitigation strategy program and carries a boxed warning regarding severe and life-threatening infections caused by Neisseria meningitidis. Patients are advised to follow all guidelines regarding meningococcal vaccinations. Always consult a qualified healthcare provider for personalized medical advice and treatment decisions.

  • What to know: Gefurulimab is a once-weekly subcutaneous treatment for specific adults with generalized myasthenia gravis.
  • Trial data: The approval is backed by the phase III PREVAIL trial showing sustained functional improvements.
  • Safety warning: The medication carries a boxed warning for serious meningococcal infections and requires appropriate vaccination.

Source medpagetoday.com — medpagetoday.com/neurology/generalneurology/123885 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.